The PennZone

TEMPE, Ariz. - PennZone -- GT Medical Technologies, Inc. today announced its GammaTile^® Surgically Targeted Radiation Therapy (STaRT) for patients with brain tumors will be spotlighted at the 2021 CNS Annual Meeting exhibition October 18-20 in Austin, Texas, and at the 15^th Tumor Section Satellite Symposium which immediately precedes it October 15-16.

"Neurological surgeons and affiliated healthcare professionals attend these prestigious events to learn about the latest advancements in neurosurgical care," said Matthew E. Likens, president and CEO of GT Medical Technologies, Inc. "We look forward to sharing our valuable data that demonstrates how GammaTile Therapy has significantly improved traditional brain tumor radiation and patient outcomes."

More on The PennZone

• Bridging Canvas and Cosmos: How Bioengineer Farin DeBose Captured the Essence of "True Science"
• RPP to host first Professional Padel Week in Miami and announce the 2026 USA Awards winners
• UK Financial Ltd. Announces Maya Preferred PRA as First Fully Verified Asset on MAYA CHAIN; Chainlink Proof of Reserve Integration Planned for Network
• ALight Technology And Services Limited Advances Through Peachscore + Dealum Accelerator and Join LvlUp Labs
• NAO Releases Shopping Intelligence to Streamline Your Quest for Value

Tumor Section Satellite Symposium
This two-day Symposium features engaging scientific sessions that explore technological advances in neurosurgical neuro-oncology. Attendees will have the opportunity to learn more about GammaTile Therapy in a Lunch Symposium on Saturday, October 16 at 12:15 p.m.

• Focus: Neurosurgical Oncology
• October 15-16 | JW Marriott, Austin Texas
• GT Medical Technologies booth 200
• Saturday, October 16, 12:15 PM-1:15 PM: GammaTile^® Therapy: Technology and Device Overview

CNS Annual Meeting
Once a year, thousands of neurosurgeons, physicians, and affiliates from around the globe come together to attend the CNS Annual Meeting to hear about the latest technological improvements in neurosurgical treatment. This will be the first in-person conference since 2019, due to the necessity of a virtual exchange in 2020. This year, attendees can visit GT Medical Technologies at booth 1750 to learn more about GammaTile Therapy.

• October 18-20 Exhibits | Austin Convention Center
• GT Medical Technologies booth 1750

About GT Medical Technologies, Inc.

More on The PennZone

• International Misophonia Foundation Launches Sensory Accessible Technology Initiative to Address Overlooked Digital Accessibility Barriers
• The Robert Travers Team of Long & Foster Marks 300+ Homes Sold, Expands Seller Representation
• CLINIMED Becomes First Liposuction Cannula Maker to Offer 3D and AR Models of Its Cannula Range
• RAS AP Consulting Advances 1099 Education and Readiness Initiative Through IFOL Training and Finance Technology Showcase
• Heritage at Manalapan Announces New 3.875% First-Year Mortgage Rate Buydown (7.11 APR)

Driven to overcome the limitations of current treatments for brain tumors and raise the standard of care, a team of brain tumor specialists joined forces and formed GT Medical Technologies with the purpose of improving the lives of patients with brain tumors. Its GammaTile Therapy received FDA 510(k) regulatory clearance for the treatment of all types of recurrent brain tumors and newly diagnosed malignant tumors. Patients receive their course of radiation while going about their daily lives, requiring no additional trips to the hospital or clinic for radiation therapy. GammaTile is available in top brain tumor centers across the United States. For more information or to find a GammaTile center near you, visit https://www.gtmedtech.com/ and follow @GTMedTech on Twitter and LinkedIn.